{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218224","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2026-05-12T12:00:07+00:00","discovered_at":"2026-05-12T12:05:00.280224+00:00","generated_at":"2026-05-12T12:20:18.531907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Tenax Q1 net loss $15.7M; cash $118.8M; Phase 3 topline data expected Q3 2026","bullets":["Net loss of $15.7M for Q1 2026 vs $10.4M in Q1 2025; R&D expense rose to $11.5M from $5.7M.","Cash and equivalents $118.8M as of March 31, 2026; expected to fund operations through at least Q1 2028.","Phase 3 LEVEL study fully randomized (>230 patients); topline data anticipated in Q3 2026.","Appointed Thomas Staab as CFO, Timothy Healey as CCO, and So-Young Kim as EVP Clinical Development.","Phase 3 LEVEL-2 trial ongoing; enrollment completion expected by end of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218224","json":"https://secwatch.observer/filing/0001193125-26-218224.json","markdown":"https://secwatch.observer/filing/0001193125-26-218224.md","text":"https://secwatch.observer/filing/0001193125-26-218224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/0001193125-26-218224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/d91737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:20:18.531907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0693ea521861245566d9abf1899e02b84cfb0c29","claim":"TENAX THERAPEUTICS, INC. reported the quarter ended March 31, 2026 results: net income $15.7 million.","evidence_excerpt":"Tenax Therapeutics reported a net loss of $15.7 million for the first quarter of 2026, compared to a net loss of $10.4 million for the first quarter of 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/0001193125-26-218224-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$15.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}